Lucilla Verna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lucilla Verna has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Giampiero Porzio
University of L’Aquila
37 shared publications Corrado Ficorella
Medical Oncology Unit,San Salvatore Hospital,University of L'Aquila,L'Aquila,Italy
25 shared publications- Federica Aielli
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
25 shared publications Katia Cannita
Department of Medical Oncology, San Salvatore Hospital, University of L'Aquila, L'Aquila, Italy
10 shared publications- Paolo Marchetti
Istituto Dermopatico dell'Immacolata,Rome,Italy, Italy
9 shared publications - Sebastiano Mercadante
Main Regional of Supportive/Palliative Care, La Maddalena Cancer Center, Department of Health Promotion, Maternal and Infant Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy
8 shared publications
Latest Publications
- 30 September 2021
- Published by SAGE Publications in Breast Disease
- Vol. 40 (4) , 257-262
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption
BACKGROUND: Despite the increase in chances of cure for early breast cancer (EBC) patients, approximately 20–45% of them will experience a disease recurrence, particularly bone metastases in 60–80% of cases, which occur more frequently in luminal subtypes. Endocrine therapy (ET) has always been the milestone of adjuvant treatment for hormone receptor-positive EBC patients, leading to indubitable reduction of disease recurrence risk. However, adjuvant aromatase inhibitors (AIs) therapy may promote a progressive decrease in bone mineral density (BMD), which can lead to osteoporosis. The increased bone resorption associated with osteoporosis may provide fertile soil for cancer growth and accelerate the development of bone metastases. PATIENTS AND METHODS: In this single-institution cohort study, we performed a retrospective analysis of “luminal-like” EBC patients who experienced bone recurrence after a subsequent disease free interval. The aim of the study was to evaluate the median time to skeletal recurrence (TSkR). RESULTS: 143 patients experienced bone recurrence. Median TSkR was 54 months (95%CI: 45–65). Among patients who received adjuvant AIs median TSkR was 35 months (95%CI: 25–54), while among patients who did not was 61 months (95%CI: 50–80) (HR = 1.45 [95%CI: 0.97–2.17], p = 0.0644). After adjusting for TNM stage (AJCC 8th edition), adjuvant AIs treatment was significantly related to a shorter TSkR (HR = 1.60 [95%CI: 1.06–2.42], p = 0.0244). Adjuvant Tamoxifen, adjuvant AIs/Tamoxifen and no-treatment did not revealed to be associated to TSkR. CONCLUSIONS: In this cohort of EBC patients with bone recurrence, AIs treatment seems to be related to a shorter TSkR. AIs-induced bone resorption might represent the underlying mechanism.
- 30 September 2021
- Published by SAGE Publications in Breast Disease
- Vol. 40 (4) , 257-262
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption
BACKGROUND: Despite the increase in chances of cure for early breast cancer (EBC) patients, approximately 20–45% of them will experience a disease recurrence, particularly bone metastases in 60–80% of cases, which occur more frequently in luminal subtypes. Endocrine therapy (ET) has always been the milestone of adjuvant treatment for hormone receptor-positive EBC patients, leading to indubitable reduction of disease recurrence risk. However, adjuvant aromatase inhibitors (AIs) therapy may promote a progressive decrease in bone mineral density (BMD), which can lead to osteoporosis. The increased bone resorption associated with osteoporosis may provide fertile soil for cancer growth and accelerate the development of bone metastases. PATIENTS AND METHODS: In this single-institution cohort study, we performed a retrospective analysis of “luminal-like” EBC patients who experienced bone recurrence after a subsequent disease free interval. The aim of the study was to evaluate the median time to skeletal recurrence (TSkR). RESULTS: 143 patients experienced bone recurrence. Median TSkR was 54 months (95%CI: 45–65). Among patients who received adjuvant AIs median TSkR was 35 months (95%CI: 25–54), while among patients who did not was 61 months (95%CI: 50–80) (HR = 1.45 [95%CI: 0.97–2.17], p = 0.0644). After adjusting for TNM stage (AJCC 8th edition), adjuvant AIs treatment was significantly related to a shorter TSkR (HR = 1.60 [95%CI: 1.06–2.42], p = 0.0244). Adjuvant Tamoxifen, adjuvant AIs/Tamoxifen and no-treatment did not revealed to be associated to TSkR. CONCLUSIONS: In this cohort of EBC patients with bone recurrence, AIs treatment seems to be related to a shorter TSkR. AIs-induced bone resorption might represent the underlying mechanism.
- 1 July 2020
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 60 (1) , e5-e7
Home Care for Cancer Patients During COVID-19 Pandemic: The Double Triage Protocol
- 1 July 2020
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 60 (1) , e5-e7
Home Care for Cancer Patients During COVID-19 Pandemic: The Double Triage Protocol
- Open Access
- 6 June 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 40 (2) , 803-812
Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen
To date, there is no consensus regarding first‑line chemotherapy for patients with HER2‑negative, locally advanced/metastatic gastric cancer (a/m GC). In the present study we reported a retrospective case‑series of patients treated with a weekly regimen containing timed‑flat infusion of 5‑fluorouracil (TFI/5‑FU), docetaxel and oxaliplatin. From June 2007 to July 2017, 32 consecutive a/m GC patients were treated with first‑line standard (st) or modulated (mod) 'FD/FOx' regimen: Weekly 12 h (from 10.00 p.m. to 10.00 a.m.) TFI/5‑FU for two consecutive nights at 900 mg/m2/day, associated to weekly alternating docetaxel, 50 mg/m2 and oxaliplatin, 80 mg/m2. The median age of the patients was 60 years and their Eastern Cooperative Oncology Group‑performance status (ECOG‑PS) was as follows: i) ECOG‑PS 0/1, (n=28, 87.5%); and ii) ECOG‑PS 2 (n=4, 12.5%). Patient activity, efficacy and safety data were collected and subgroup analyses were conducted among patients treated with st and mod FD/FOx. In the intention‑to‑treat (ITT) analysis, the objective response rate (ORR) was 75% (95% CI, 53‑90) and the disease control rate (DCR) was 87.5% (95% CI, 67.6‑97.3). After a median follow‑up of 16 months, median progression‑free survival (PFS) and median overall survival (OS) were 14.0 and 19.0 months, respectively. The received dose‑intensities were ~80% of the standard doses for each agent. The most relevant treatment‑related grade 3 adverse events were: Neutropenia (40.6%), asthenia (18.7%) and diarrhea (18.7%). The only treatment‑related grade 4 adverse event was neutropenia (9.3%). No febrile neutropenia was observed and none of the patients died as a result of adverse events. FD/FOx regimen appeared to be a feasible option as a first‑line treatment of a/m GC patients, especially in case of high‑tumor burden, with the need of rapid tumor shrinkage and disease‑related symptoms palliation.
- 6 June 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 40 (2) , 803-812
Open AccessTimed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen
To date, there is no consensus regarding first‑line chemotherapy for patients with HER2‑negative, locally advanced/metastatic gastric cancer (a/m GC). In the present study we reported a retrospective case‑series of patients treated with a weekly regimen containing timed‑flat infusion of 5‑fluorouracil (TFI/5‑FU), docetaxel and oxaliplatin. From June 2007 to July 2017, 32 consecutive a/m GC patients were treated with first‑line standard (st) or modulated (mod) 'FD/FOx' regimen: Weekly 12 h (from 10.00 p.m. to 10.00 a.m.) TFI/5‑FU for two consecutive nights at 900 mg/m2/day, associated to weekly alternating docetaxel, 50 mg/m2 and oxaliplatin, 80 mg/m2. The median age of the patients was 60 years and their Eastern Cooperative Oncology Group‑performance status (ECOG‑PS) was as follows: i) ECOG‑PS 0/1, (n=28, 87.5%); and ii) ECOG‑PS 2 (n=4, 12.5%). Patient activity, efficacy and safety data were collected and subgroup analyses were conducted among patients treated with st and mod FD/FOx. In the intention‑to‑treat (ITT) analysis, the objective response rate (ORR) was 75% (95% CI, 53‑90) and the disease control rate (DCR) was 87.5% (95% CI, 67.6‑97.3). After a median follow‑up of 16 months, median progression‑free survival (PFS) and median overall survival (OS) were 14.0 and 19.0 months, respectively. The received dose‑intensities were ~80% of the standard doses for each agent. The most relevant treatment‑related grade 3 adverse events were: Neutropenia (40.6%), asthenia (18.7%) and diarrhea (18.7%). The only treatment‑related grade 4 adverse event was neutropenia (9.3%). No febrile neutropenia was observed and none of the patients died as a result of adverse events. FD/FOx regimen appeared to be a feasible option as a first‑line treatment of a/m GC patients, especially in case of high‑tumor burden, with the need of rapid tumor shrinkage and disease‑related symptoms palliation.
- 24 May 2018
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 17 (1) , 82-86
The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study
One of the first steps to early integrate palliative care into oncology practice is a timely and efficient evaluation of symptoms (Bakitas et al., 2015; Davis et al., 2015; Temel et al., 2010). In a recent position paper, the Italian Association of Medical Oncology tells oncologists that they “must be able to prevent, recognize, measure, and treat all cancer-related symptoms” (Zagonel et al., 2017). Major international scientific societies such as the American Society of Clinical Oncology and the European Society of Medical Oncology have often defined the key role of symptoms evaluation and management to force the integration of palliative care into oncology (Davis et al., 2015; Ferrel et al., 2017). Nevertheless, a recent survey conducted by the Italian Association of Medical Oncology shows that only 20% of oncologists regularly uses valid tools to evaluate symptoms, 45% exclusively use them in the context of clinical trials, 30% use them only occasionally, and 5% never use them (Zagonel et al., 2016).
- 24 May 2018
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 17 (1) , 82-86
The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study
One of the first steps to early integrate palliative care into oncology practice is a timely and efficient evaluation of symptoms (Bakitas et al., 2015; Davis et al., 2015; Temel et al., 2010). In a recent position paper, the Italian Association of Medical Oncology tells oncologists that they “must be able to prevent, recognize, measure, and treat all cancer-related symptoms” (Zagonel et al., 2017). Major international scientific societies such as the American Society of Clinical Oncology and the European Society of Medical Oncology have often defined the key role of symptoms evaluation and management to force the integration of palliative care into oncology (Davis et al., 2015; Ferrel et al., 2017). Nevertheless, a recent survey conducted by the Italian Association of Medical Oncology shows that only 20% of oncologists regularly uses valid tools to evaluate symptoms, 45% exclusively use them in the context of clinical trials, 30% use them only occasionally, and 5% never use them (Zagonel et al., 2016).
- 1 June 2017
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 27 (3) , 258-267
Characterization of melanoma susceptibility genes in high-risk patients from Central Italy
Genetic susceptibility to cutaneous melanoma has been investigated in Italian high-risk melanoma patients from different geographical regions. CDKN2A,CDK4, andMC1Rgenes have been screened in most studies,MITFandPOT1were screened in only one study, and none analyzed theTERTpromoter. We carried out a mutational analysis ofCDKN2A,CDK4exon 2,POT1p.S270N,MITFexon 10,MC1R, and theTERTpromoter in 106 high-risk patients with familial melanoma (FM) and sporadic multiple primary melanoma (spMPM) from Central Italy and evaluated mutations according to the clinicopathological characteristics of patients and lesions. In FM,CDKN2Amutations were detected in 8.3% of the families, including one undescribed exon 1β mutation (p.T31M), and their prevalence increased with the number of affected relatives within the family.MC1Rvariants were identified in 65% of the patients and theTERTrs2853669 promoter polymorphism was identified in 58% of the patients. A novel synonymous mutation detected inMITFexon 10 (c.861A>G, p.E287E), although predicted as a splice site mutation by computational tools, could not functionally be confirmed to alter splicing. For spMPM, 3% carriedCDKN2Amutations, 79% carriedMC1Rvariants, and 47% carried theTERTrs2853669 promoter polymorphism.MC1Rvariants were associated with fair skin type and light hair color both in FM and in spMPM, and with a reduction of age at diagnosis in FM patients. Mutations inCDK4exon 2 and thePOT1p.S270N mutation were not detected. A low frequency ofCDKN2Amutations and a high prevalence ofMC1Rvariants characterize high-risk melanoma patients from Central Italy.
- 1 June 2017
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 27 (3) , 258-267
Characterization of melanoma susceptibility genes in high-risk patients from Central Italy
Genetic susceptibility to cutaneous melanoma has been investigated in Italian high-risk melanoma patients from different geographical regions. CDKN2A,CDK4, andMC1Rgenes have been screened in most studies,MITFandPOT1were screened in only one study, and none analyzed theTERTpromoter. We carried out a mutational analysis ofCDKN2A,CDK4exon 2,POT1p.S270N,MITFexon 10,MC1R, and theTERTpromoter in 106 high-risk patients with familial melanoma (FM) and sporadic multiple primary melanoma (spMPM) from Central Italy and evaluated mutations according to the clinicopathological characteristics of patients and lesions. In FM,CDKN2Amutations were detected in 8.3% of the families, including one undescribed exon 1β mutation (p.T31M), and their prevalence increased with the number of affected relatives within the family.MC1Rvariants were identified in 65% of the patients and theTERTrs2853669 promoter polymorphism was identified in 58% of the patients. A novel synonymous mutation detected inMITFexon 10 (c.861A>G, p.E287E), although predicted as a splice site mutation by computational tools, could not functionally be confirmed to alter splicing. For spMPM, 3% carriedCDKN2Amutations, 79% carriedMC1Rvariants, and 47% carried theTERTrs2853669 promoter polymorphism.MC1Rvariants were associated with fair skin type and light hair color both in FM and in spMPM, and with a reduction of age at diagnosis in FM patients. Mutations inCDK4exon 2 and thePOT1p.S270N mutation were not detected. A low frequency ofCDKN2Amutations and a high prevalence ofMC1Rvariants characterize high-risk melanoma patients from Central Italy.
- 1 May 2017
- Published by SAGE Publications in Tumori Journal
- Vol. 103 (3) , e23
Integration between Oncology and Palliative Care: A Plan for the Next Decade?
- 1 May 2017
- Published by SAGE Publications in Tumori Journal
- Vol. 103 (3) , e23
Integration between Oncology and Palliative Care: A Plan for the Next Decade?
- Open Access
- 12 January 2017
- Published by Cambridge University Press (CUP) in Disaster Medicine and Public Health Preparedness
- Vol. 11 (1) , 4-6
Caring for Cancer Patients After the Italian Earthquakes: A Proposal From the Field
Paper triage tags can be considered old-fashioned in a certain way, especially when compared with wireless electronic devices. However, we believe that paper tags are still the first choice in disaster drill or education, with the advantage of a low initial cost. We hope that improvement in the design of paper triage tags will contribute to improving the operational capacity of students or trainees.
- 12 January 2017
- Published by Cambridge University Press (CUP) in Disaster Medicine and Public Health Preparedness
- Vol. 11 (1) , 4-6
Open AccessCaring for Cancer Patients After the Italian Earthquakes: A Proposal From the Field
Paper triage tags can be considered old-fashioned in a certain way, especially when compared with wireless electronic devices. However, we believe that paper tags are still the first choice in disaster drill or education, with the advantage of a low initial cost. We hope that improvement in the design of paper triage tags will contribute to improving the operational capacity of students or trainees.
- Open Access
- 1 January 2017
- Published by Scientific Scholar in Indian Journal of Palliative Care
- Vol. 23 (3) , 350-352
Topical menthol for treatment of chemotherapy-induced peripheral neuropathy
Chemotherapy-induced peripheral neuropathy is a frequent treatment-limiting factor that significantly impairs patients' everyday life, also because of a lack of valid palliative options. Here, we report a case of a male patient with a history of metastatic colon cancer and previous chemotherapies. He came to our attention with a peripheral neuropathy that impaired his quality of life and could limit the further line of chemotherapy. We treated the neuropathy with menthol aqueous cream with benefit.
- 1 January 2017
- Published by Scientific Scholar in Indian Journal of Palliative Care
- Vol. 23 (3) , 350-352
Open AccessTopical menthol for treatment of chemotherapy-induced peripheral neuropathy
Chemotherapy-induced peripheral neuropathy is a frequent treatment-limiting factor that significantly impairs patients' everyday life, also because of a lack of valid palliative options. Here, we report a case of a male patient with a history of metastatic colon cancer and previous chemotherapies. He came to our attention with a peripheral neuropathy that impaired his quality of life and could limit the further line of chemotherapy. We treated the neuropathy with menthol aqueous cream with benefit.
- 16 June 2016
- Published by Springer Nature in Drugs
- Vol. 76 (10) , 1059-1061
Comment on ‘What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain: Expert Opinion’
- 16 June 2016
- Published by Springer Nature in Drugs
- Vol. 76 (10) , 1059-1061
Comment on ‘What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain: Expert Opinion’